NEW YORK (GenomeWeb News) – Amgen expanded an R&D licensing agreement to include the evaluation of Selexis' Sure Cho-M Cell Line.

Under the terms of the deal announced today by Selexis, Amgen will assess the cell line in conjunction with the Selexis SUREtech Vectors for improved R&D. Sure Cho-M Cell Line is a mammalian cell line derived from CHO-K1 cells and is for producing therapeutic recombinant proteins and monoclonal antibodies.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.